UnitedHealth Group Stock Falls 3.37% Amid Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy UNH?
Source: NASDAQ.COM
- Stock Performance: UnitedHealth Group (UNH) closed at $259.02, reflecting a 3.37% decline from the previous day, underperforming the S&P 500's 1.67% drop, indicating market concerns regarding its future profitability.
- Industry Performance: Over the past month, UNH's stock has fallen by 6.49%, contributing to a 7.36% loss in the Medical sector, which is significantly worse than the S&P 500's 6.15% decline, highlighting the company's relative weakness in the industry.
- Earnings Expectations: The company is expected to release its earnings report on April 21, 2026, with consensus estimates forecasting an EPS of $6.62, an 8.06% year-over-year decline, and revenue of $110.08 billion, indicating a modest 0.46% growth, suggesting signs of stagnation.
- Valuation Analysis: UnitedHealth Group currently trades at a Forward P/E ratio of 15.15, aligning with the industry average, but its PEG ratio of 1.23 exceeds the industry average of 0.94, suggesting higher market expectations for future growth, which may also indicate valuation pressure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 268.050
Low
330.00
Averages
397.82
High
444.00
Current: 268.050
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health offers comprehensive and patient-centered care, addressing the physical, mental, social, and financial well-being. Optum Health delivers primary, specialty and surgical care; helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UnitedHealth Group Stock Falls 3.37% Amid Market Decline
- Stock Performance: UnitedHealth Group (UNH) closed at $259.02, reflecting a 3.37% decline from the previous day, underperforming the S&P 500's 1.67% drop, indicating market concerns regarding its future profitability.
- Industry Performance: Over the past month, UNH's stock has fallen by 6.49%, contributing to a 7.36% loss in the Medical sector, which is significantly worse than the S&P 500's 6.15% decline, highlighting the company's relative weakness in the industry.
- Earnings Expectations: The company is expected to release its earnings report on April 21, 2026, with consensus estimates forecasting an EPS of $6.62, an 8.06% year-over-year decline, and revenue of $110.08 billion, indicating a modest 0.46% growth, suggesting signs of stagnation.
- Valuation Analysis: UnitedHealth Group currently trades at a Forward P/E ratio of 15.15, aligning with the industry average, but its PEG ratio of 1.23 exceeds the industry average of 0.94, suggesting higher market expectations for future growth, which may also indicate valuation pressure.
See More
U.S. Senate Reaches Funding Deal for Homeland Security Department
- Funding Deal for DHS: The U.S. Senate reached a funding agreement early this morning for the Department of Homeland Security, indicating progress toward ending the department's shutdown, although the bill excludes funding for Immigration and Customs Enforcement, which may impact immigration policy enforcement.
- Market Volatility Intensifies: Following Trump's announcement to extend the pause on attacks against Iran's nuclear facilities, the S&P 500 recorded its largest one-day loss in over two months, with crude prices surpassing $110 per barrel, reflecting the market's sensitivity to geopolitical risks.
- AI Legal Victory: AI firm Anthropic secured a preliminary injunction in federal court against the Pentagon's blacklisting, with the judge labeling the action as “classic illegal First Amendment retaliation,” which could affect government collaborations with AI companies.
- Fed Nomination Controversy: Senator Elizabeth Warren issued a scathing letter to Kevin Warsh, Trump's pick for Federal Reserve Chair, stating his past failures should disqualify him from promotion, potentially influencing the Fed's future policy direction.
See More
British Airways Introduces Emission Reduction Incentives for Pilots
- Emission Reduction Incentive: British Airways has launched a new initiative encouraging pilots to reduce aircraft carbon dioxide emissions by 60,000 tons beyond 2025 levels to earn a bonus worth 1% of their base pay, addressing the rising jet fuel prices.
- Collaboration with Union: The airline is working with the British Airline Pilots' Association (BALPA) to vote on this proposal at the end of April, with implementation expected next year, demonstrating the company's commitment to improving pilots' work experience.
- Surging Fuel Prices: Amid the U.S.-Iran conflict, global jet fuel prices have surged by 106%, with international benchmark Brent crude nearing $107 per barrel, forcing airlines to consider raising ticket prices or canceling unprofitable flights.
- Industry Impact: The incentive reflects the airline industry's response to high fuel cost pressures, as other carriers like Cathay Pacific and Qantas also adjust fares to cope with rising costs, highlighting the challenges faced across the sector.
See More
UNITEDHEALTH TO INVEST $1.6 BILLION IN AI THIS YEAR
- Investment Amount: The United Health Plan has allocated $1.6 billion for investments this year.
- Focus Areas: The investments are aimed at enhancing healthcare services and improving health outcomes.
See More
UNITEDHEALTHCARE LAUNCHES AVERY, A GENERATIVE AI ASSISTANT FOR HEALTH CARE NAVIGATION
Introduction of AI in Health Care: United Health has launched a new AI companion designed to assist with health care navigation.
Generative AI Technology: The AI tool utilizes generative technology to enhance patient experiences and streamline health care processes.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
UnitedHealth Group Stock Falls 3.37% Amid Market Decline
- Stock Performance: UnitedHealth Group (UNH) closed at $259.02, reflecting a 3.37% decline from the previous day, underperforming the S&P 500's 1.67% drop, indicating market concerns regarding its future profitability.
- Industry Performance: Over the past month, UNH's stock has fallen by 6.49%, contributing to a 7.36% loss in the Medical sector, which is significantly worse than the S&P 500's 6.15% decline, highlighting the company's relative weakness in the industry.
- Earnings Expectations: The company is expected to release its earnings report on April 21, 2026, with consensus estimates forecasting an EPS of $6.62, an 8.06% year-over-year decline, and revenue of $110.08 billion, indicating a modest 0.46% growth, suggesting signs of stagnation.
- Valuation Analysis: UnitedHealth Group currently trades at a Forward P/E ratio of 15.15, aligning with the industry average, but its PEG ratio of 1.23 exceeds the industry average of 0.94, suggesting higher market expectations for future growth, which may also indicate valuation pressure.
See More
U.S. Senate Reaches Funding Deal for Homeland Security Department
- Funding Deal for DHS: The U.S. Senate reached a funding agreement early this morning for the Department of Homeland Security, indicating progress toward ending the department's shutdown, although the bill excludes funding for Immigration and Customs Enforcement, which may impact immigration policy enforcement.
- Market Volatility Intensifies: Following Trump's announcement to extend the pause on attacks against Iran's nuclear facilities, the S&P 500 recorded its largest one-day loss in over two months, with crude prices surpassing $110 per barrel, reflecting the market's sensitivity to geopolitical risks.
- AI Legal Victory: AI firm Anthropic secured a preliminary injunction in federal court against the Pentagon's blacklisting, with the judge labeling the action as “classic illegal First Amendment retaliation,” which could affect government collaborations with AI companies.
- Fed Nomination Controversy: Senator Elizabeth Warren issued a scathing letter to Kevin Warsh, Trump's pick for Federal Reserve Chair, stating his past failures should disqualify him from promotion, potentially influencing the Fed's future policy direction.
See More
British Airways Introduces Emission Reduction Incentives for Pilots
- Emission Reduction Incentive: British Airways has launched a new initiative encouraging pilots to reduce aircraft carbon dioxide emissions by 60,000 tons beyond 2025 levels to earn a bonus worth 1% of their base pay, addressing the rising jet fuel prices.
- Collaboration with Union: The airline is working with the British Airline Pilots' Association (BALPA) to vote on this proposal at the end of April, with implementation expected next year, demonstrating the company's commitment to improving pilots' work experience.
- Surging Fuel Prices: Amid the U.S.-Iran conflict, global jet fuel prices have surged by 106%, with international benchmark Brent crude nearing $107 per barrel, forcing airlines to consider raising ticket prices or canceling unprofitable flights.
- Industry Impact: The incentive reflects the airline industry's response to high fuel cost pressures, as other carriers like Cathay Pacific and Qantas also adjust fares to cope with rising costs, highlighting the challenges faced across the sector.
See More
UNITEDHEALTH TO INVEST $1.6 BILLION IN AI THIS YEAR
- Investment Amount: The United Health Plan has allocated $1.6 billion for investments this year.
- Focus Areas: The investments are aimed at enhancing healthcare services and improving health outcomes.
See More
UNITEDHEALTHCARE LAUNCHES AVERY, A GENERATIVE AI ASSISTANT FOR HEALTH CARE NAVIGATION
Introduction of AI in Health Care: United Health has launched a new AI companion designed to assist with health care navigation.
Generative AI Technology: The AI tool utilizes generative technology to enhance patient experiences and streamline health care processes.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
